Homozygous familial hypercholesterolemia
Information
- Disease name
- Homozygous familial hypercholesterolemia
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT05217667 | Active, not recruiting | Phase 2 | Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH) | April 22, 2022 | May 2025 |
| NCT05611528 | Active, not recruiting | Phase 3 | Safety and Effectiveness of Evinacumab for the Treatment of Homozygous Familial Hypercholesterolemia | February 21, 2023 | February 2026 |
| NCT01412034 | Completed | Phase 2 | Effect of CER-001 on Plaque Volume in Homozygous Familial Hypercholesterolemia (HoFH) Subjects | November 2011 | August 2014 |
| NCT01556906 | Completed | Phase 2 | Safety, Tolerability and Efficacy of Microsomal Triglyceride Protein (MTP) Inhibitor | June 2003 | February 2004 |
| NCT01588496 | Completed | Phase 2/Phase 3 | Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities | April 5, 2012 | January 31, 2014 |
| NCT01878604 | Completed | Gene Analysis and Treatment Optimization in Chinese Homozygous Familial Hypercholesterolemia | October 2001 | January 2015 | |
| NCT00704535 | Completed | Evaluation of the Safety, Tolerability and Efficacy of Ezetimibe on a Select Population of Filipinos With Hypercholesterolemia (Study P04748)(COMPLETED) | March 2006 | April 2008 | |
| NCT00730236 | Completed | Phase 3 | A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH) | December 2007 | October 2011 |
| NCT03156621 | Completed | Phase 3 | Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH) | October 3, 2017 | February 13, 2020 |
| NCT03234127 | Completed | N/A | Study of cardiovAscular Contrasted Phenotypes in Patients With FamIliaI hypercholesteRolemia | December 6, 2017 | May 6, 2021 |
| NCT03399786 | Completed | Phase 3 | Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia | January 18, 2018 | March 17, 2020 |
| NCT03409744 | Completed | Phase 3 | Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia | March 13, 2018 | April 13, 2023 |
| NCT03814187 | Completed | Phase 3 | Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C | April 16, 2019 | February 13, 2023 |
| NCT03851705 | Completed | Phase 3 | A Study of Inclisiran in Participants With Homozygous Familial Hypercholesterolemia (HoFH) | February 6, 2019 | September 9, 2021 |
| NCT03933293 | Completed | Phase 2 | A Study to Evaluate the Safety and Efficacy of the PCSK9 Inhibitor AK102 in Patients With HoFH | May 13, 2019 | March 15, 2021 |
| NCT04031742 | Completed | Phase 2/Phase 3 | A Study to Evaluate Safety and Efficacy of IBI306, a PCSK9 Monoclonal Antibody in Chinese Subjects With Homozygous Familial Hypercholesterolemia | September 29, 2019 | December 30, 2021 |
| NCT04034485 | Completed | Phase 3 | Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH | December 7, 2019 | January 30, 2023 |
| NCT04233918 | Completed | Phase 3 | Evaluate the Efficacy and Safety of Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia | June 29, 2020 | May 30, 2023 |
| NCT02265952 | Completed | Phase 2 | Study of REGN1500 in Participants With Homozygous Familial Hypercholesterolemia (HoFH) | February 4, 2015 | July 23, 2018 |
| NCT02286596 | Completed | Comparisons of Two Low-density Lipoprotein Apheresis Systems in Patients With Homozygous Familial Hypercholesterolemia | April 2013 | December 2014 | |
| NCT02472535 | Completed | Phase 2 | Study to Evaluate the Effects of MBX-8025 in Patients With HoFH | April 2015 | February 2016 |
| NCT02963311 | Completed | Phase 2 | A Study of ALN-PCSSC in Participants With Homozygous Familial Hypercholesterolemia (HoFH) | December 13, 2016 | October 8, 2018 |
| NCT06009393 | Not yet recruiting | Phase 2 | Evaluate the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia | September 24, 2023 | August 18, 2024 |
| NCT06125847 | Recruiting | Early Phase 1 | NGGT006 Gene Therapy for Homozygous Familial Hypercholesterolemia | October 29, 2023 | November 2028 |
| NCT01109368 | Recruiting | The Rogosin Institute Homozygous Familial Hypercholesterolemia Repository | June 2010 | May 2025 | |
| NCT02135705 | Recruiting | LOWER: Lomitapide Observational Worldwide Evaluation Registry | March 18, 2014 | September 1, 2028 | |
| NCT04815005 | Recruiting | HoFH, the International Clinical Collaborators Registry | January 24, 2017 | December 31, 2025 | |
| NCT01841684 | Terminated | Phase 3 | Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042) | June 2013 | June 2014 |
| NCT03135184 | Unknown status | N/A | HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia | January 26, 2018 | August 2019 |
| NCT02765841 | Withdrawn | Phase 3 | Evaluate the Efficacy and Safety of Lomitapide in Pediatric Patients With Homozygous Familial Hypercholesterolemia on Stable Lipid-lowering Therapy | May 2016 | December 2019 |
| NCT03455777 | Withdrawn | Phase 2 | Study of AKCEA-ANGPTL3-LRX (ISIS 703802) in Patients With Homozygous Familial Hypercholesterolemia (HoFH) | April 12, 2018 | December 31, 2018 |
| NCT02399852 | Withdrawn | Effects of Lomitapide on Carotid and Aortic Atherosclerosis | June 2015 | December 2021 |